Free Trial

TG Therapeutics Stock 300% Rally Has Legs Yet

TG Therapeutics Stock 300% Rally Has Legs Yet

Key Points

It’s been a while since the Marketbeat team flagged a hot stock that had already logged a 300% rally but looked like it was going to go higher. But the New York-headquartered TG Therapeutics Inc NASDAQ: TGTX is worth every word. Their shares have tacked on as much as 275% since the middle of November and there are several signs to suggest that momentum is only continuing to build. 
To get a clear idea of what the stock might do in the coming months, it’s necessary to understand the catalysts and drivers that have sent it so high. Buckle up.

Like most small-cap and mid-cap biotechs, TG Therapeutics’ stock chart in recent years is mostly defined by updates, be they positive or negative, in relation to their FDA trials and the madness of crowds.

Their shares got swept up in the COVID rally and ran from $5 to $50, only to come back to $5 again last summer. But having started to fade into obscurity by the fall as the stock got used to being in a downtrend, one update changed all that. 

FDA Updates

News that the company had begun labeling discussions with the FDA ahead of a potential U.S. approval for its multiple sclerosis (MS) therapy ublituximab sent the shorts scrambling to cover and the bulls to buy. The stock jumped 90% over the next three days, and while the surge petered out, shares consolidated around most of the gains. Then came the company’s PDUFA date at the end of December, arguably the most watched event for many small biotechs.

It’s the date the FDA has shared in advance for when they’re aiming to give a final decision on a company’s new drug application. The positive signs from November held through, approval was confirmed, and the stock popped again. This time it jumped 50% in the following three days, and it hasn’t looked back since. 

That rally is still going, with TG Therapeutics’ stock notching fresh highs only yesterday and tagging a 292% return from the first week of November. The shares saw some selling in yesterday’s afternoon session before rallying into the close. This kind of volatility is almost certain to remain, with the stock’s RSI well above 70, indicating extremely overbought conditions. But this makes TG Therapeutics a compelling stock to add to your watchlist. 

As longer-term investors take profits and the stock seesaws, those keen to get involved in early-stage biotech on the FDA’s right side should see some interesting buying opportunities opening up. And more eyes than ever before are watching the stock now. 

Getting Involved Now

Last month, one of the company directors disclosed fresh insider purchases to increase his stake, a move Wall Street loves to see that gives investors confidence. And only yesterday, the team over at Cantor Fitzgerald was out with a bullish review of the stock’s prospects. Analyst Prakhar Agrawal and his team expect a “strong” commercial rollout for the company’s new MS therapy, now being marketed as Briumvi. 

As part of the update, Agrawal reiterated his Overweight rating and upped his price target on TG Therapeutics shares from the $18 they’re trading at this week to $24. This points to further upside in the region of 30% yet to be realized, which should be more than enough to get even the more risk-averse investor interested. 

Like most biotechs out there, investors have to be careful. Those stocks have a bad habit of rallying into, often through, the news but then fading from the headlines and losing momentum. Tight risk management is critical, which is why we wouldn’t advise to jump in head first. Let’s see how shares trade through this week and if some interesting buying opportunities open up to make that targeted 30% upside even better.

Should You Invest $1,000 in TG Therapeutics Right Now?

Before you consider TG Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.

While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Sam Quirke
About The Author

Sam Quirke

Contributing Author

Contributing Author

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
TG Therapeutics (TGTX)
4.425 of 5 stars
$33.49-3.2%N/A90.51Moderate Buy$49.00
Compare These Stocks  Add These Stocks to My Watchlist